John Zajecka to Antidepressive Agents, Second-Generation
This is a "connection" page, showing publications John Zajecka has written about Antidepressive Agents, Second-Generation.
Connection Strength
0.566
-
Antidepressant dosing and switching guidelines: focus on nefazodone. J Clin Psychiatry. 2002; 63 Suppl 1:42-7.
Score: 0.177
-
A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med. 2000 May 18; 342(20):1462-70.
Score: 0.158
-
Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release. J Affect Disord. 2010 Nov; 126(3):420-9.
Score: 0.079
-
A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol. 2005 Oct; 25(5):441-7.
Score: 0.057
-
Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. Int Clin Psychopharmacol. 2003 May; 18(3):151-6.
Score: 0.049
-
Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. J Clin Psychiatry. 2002 May; 63(5):434-41.
Score: 0.045